pre-seed
Stage
About
TippingPoint Biosciences develops novel therapeutics targeting dysfunctional chromatin networks to treat diseases, including certain cancers, by drugging previously undruggable chromatin states with improved specificity and reduced toxicity.
Explore TippingPoint Biosciences's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.